Objective The modification of Chinese patent medicines (CPM) instructions is currently the focus of national drug regulation, with policies and regulations being established. Nevertheless, the policies pertaining to CPM instructions have not been thoroughly investigated. This study analyzes the direction and current issues with existing policy items to give a reference for future optimization and adjustment of policies linked to CPM instructions. Methods The official website of the National Medical Products Administration (NMPA) and National Health Commission (NHC) were searched to collect policy documents related to the CPM instructions issued at the national level in China from January 1st 2000 to June 1st 2024. Based on the classification of policy tools (supply-based policy tools, demand-based policy tools, environment-based policy tools) and the dimension of policy development (policy planning, policy implementation, policy supervision, and policy evaluation ), a two-dimensional analytical framework of "policy tools and policy process" was constructed by using the content analysis method and the quantitative analysis method, and policy documents were analyzed. Results The 27 policy texts included in the analysis generated 104 policy entries in total, wherein, environment-based policy tools (74.04%) were used the most in the dimension of policy tools, followed by demand-based policy tools (24.04%) and supply-based policy tools (1.92%). In the dimension of policy development, policy planning tools, policy implementation tools, policy supervision tools, and policy evaluation tools accounted for 24.04%, 52.88%, 17.31%, and 5.77%, respectively. An in-depth analysis of the content of the policy entries discovered that the existing policy took into account the specification of the content of the instruction and the standardization of the expression of writing, the instruction application guidance, etc, and more and more attention was being paid to the content of the characteristics of TCM in the instruction. Conclusion Currently, there is an insufficient amount of policy documents on CPM standards, which are overly focused on environment-based policy tools and the policy implementation process. To achieve the policy goal of regulating and applying CPM specifications, it is recommended to create a balanced and coordinated structure of policy instruments, emphasise the direct promotion and pulling effect of supply and demand, increase the weight of policy evaluation and supervision, and develop a standard system for evaluating CPM specifications.
Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved
1. |
王晶. 2010-2020年我国中成药药品说明书修订情况分析. 中国药房, 2021, 32(4): 392-398.
|
2. |
邵蓉, 蒋正华, 黄泰康. 医疗机构涉药人员执业风险防范与规避. 中国药房, 2007, (28): 2163-2164.
|
3. |
侯鸿军, 王莉, 李兴民, 等. 我国中成药说明书现状、存在问题及对策建议. 中国食品药品监管, 2020, (2): 32-39.
|
4. |
夏冕, 高艺宁, 陈芝玲, 等. 政策工具视角下我国公立医院薪酬政策文本分析. 中国卫生政策研究, 2023, 16(12): 1-8.
|
5. |
曲纵翔, 汪峻宇. 政策工具、战略过程及参与主体: 乡村振兴战略演进的三维架构研究—基于148份中央政策文本的量化分析. 中共福建省委党校(福建行政学院)学报, 2021, (1): 79-91.
|
6. |
荣红国, 邢叶一祎, 董玥, 等. 政策工具视角下我国抗菌药物合理用药政策研究. 中国卫生政策研究, 2021, 14(8): 45-51.
|
7. |
全国机关事务管理研究会. 政策工具视角下低效闲置国有资产盘活利用政策的优化建议. 2024.
|
8. |
朱欣叶, 钱爱兵. 我国中成药政策文本的量化分析. 南京中医药大学学报(社会科学版), 2023, 24(5): 345-350.
|
9. |
国务院办公厅. 国务院办公厅关于印发“十四五”中医药发展规划的通知. 2022.
|
10. |
国家药品监督管理局. 已上市中药说明书安全信息项内容修订技术指导原则(试行). 2022.
|
- 1. 王晶. 2010-2020年我国中成药药品说明书修订情况分析. 中国药房, 2021, 32(4): 392-398.
- 2. 邵蓉, 蒋正华, 黄泰康. 医疗机构涉药人员执业风险防范与规避. 中国药房, 2007, (28): 2163-2164.
- 3. 侯鸿军, 王莉, 李兴民, 等. 我国中成药说明书现状、存在问题及对策建议. 中国食品药品监管, 2020, (2): 32-39.
- 4. 夏冕, 高艺宁, 陈芝玲, 等. 政策工具视角下我国公立医院薪酬政策文本分析. 中国卫生政策研究, 2023, 16(12): 1-8.
- 5. 曲纵翔, 汪峻宇. 政策工具、战略过程及参与主体: 乡村振兴战略演进的三维架构研究—基于148份中央政策文本的量化分析. 中共福建省委党校(福建行政学院)学报, 2021, (1): 79-91.
- 6. 荣红国, 邢叶一祎, 董玥, 等. 政策工具视角下我国抗菌药物合理用药政策研究. 中国卫生政策研究, 2021, 14(8): 45-51.
- 7. 全国机关事务管理研究会. 政策工具视角下低效闲置国有资产盘活利用政策的优化建议. 2024.
- 8. 朱欣叶, 钱爱兵. 我国中成药政策文本的量化分析. 南京中医药大学学报(社会科学版), 2023, 24(5): 345-350.
- 9. 国务院办公厅. 国务院办公厅关于印发“十四五”中医药发展规划的通知. 2022.
- 10. 国家药品监督管理局. 已上市中药说明书安全信息项内容修订技术指导原则(试行). 2022.